Journal article
Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE® in an Animal Model of Multiple Sclerosis
Frontiers in immunology, Vol.10, pp.462-462
03/22/2019
DOI: 10.3389/fimmu.2019.00462
PMCID: PMC6448018
PMID: 30984162
Abstract
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. We and others have shown that there is enrichment or depletion of some gut bacteria in MS patients compared to healthy controls (HC), suggesting an important role of the gut bacteria in disease pathogenesis. Thus, specific gut bacteria that are lower in abundance in MS patients could be used as a potential treatment option for this disease. In particular, we and others have shown that MS patients have a lower abundance of
Prevotella
compared to HC, whereas the abundance of
Prevotella
is increased in patients that receive disease-modifying therapies such as Copaxone® (Glatiramer acetate-GA). This inverse correlation between the severity of MS disease and the abundance of
Prevotella
suggests its potential for use as a therapeutic option to treat MS. Notably we have previously identified a specific strain
, Prevotella histicola
(
P. histicola
), that suppresses disease in the animal model of MS, experimental autoimmune encephalomyelitis (EAE) compared with sham treatment. In the present study we analyzed whether the disease suppressing effects of
P. histicola
synergize with those of the disease-modifying drug Copaxone® to more effectively suppress disease compared to either treatment alone. Treatment with
P. histicola
was as effective in suppressing disease as treatment with Copaxone®, whereas the combination of
P. histicola
plus Copaxone® was not more effective than either individual treatment.
P. histicola
-treated mice had an increased frequency and number of CD4
+
FoxP3
+
regulatory T cells in periphery as well as gut and a decreased frequency of pro-inflammatory IFN-γ and IL17-producing CD4 T cells in the CNS, suggesting
P. histicola
suppresses disease by boosting anti-inflammatory immune responses and inhibiting pro-inflammatory immune responses. In conclusion, our study indicates that the human gut commensal
P. histicola
can suppress disease as efficiently as Copaxone® and may provide an alternative treatment option for MS patients.
Details
- Title: Subtitle
- Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE® in an Animal Model of Multiple Sclerosis
- Creators
- Shailesh K Shahi - Department of Pathology, University of IowaSamantha N Freedman - Graduate Program in Immunology, University of IowaAlexandra C Murra - Department of Pathology, University of IowaKasra Zarei - Medical Scientist Training Program, University of IowaRamakrishna Sompallae - Department of Pathology, University of IowaKatherine N Gibson-Corley - Department of Pathology, University of IowaNitin J Karandikar - Department of Pathology, University of IowaJoseph A Murray - Department of Immunology, Mayo ClinicAshutosh K Mangalam - Department of Pathology, University of Iowa
- Resource Type
- Journal article
- Publication Details
- Frontiers in immunology, Vol.10, pp.462-462
- DOI
- 10.3389/fimmu.2019.00462
- PMID
- 30984162
- PMCID
- PMC6448018
- NLM abbreviation
- Front Immunol
- ISSN
- 1664-3224
- eISSN
- 1664-3224
- Publisher
- Frontiers Media S.A
- Language
- English
- Date published
- 03/22/2019
- Academic Unit
- The University of Iowa Institute for Vision Research; Pathology; Iowa Neuroscience Institute; Family and Community Medicine; Ophthalmology and Visual Sciences
- Record Identifier
- 9984070442102771
Metrics
27 Record Views